IS5809A - Concomitant administration of ACAT and MMP inhibitors for the treatment of fat degeneration - Google Patents

Concomitant administration of ACAT and MMP inhibitors for the treatment of fat degeneration

Info

Publication number
IS5809A
IS5809A IS5809A IS5809A IS5809A IS 5809 A IS5809 A IS 5809A IS 5809 A IS5809 A IS 5809A IS 5809 A IS5809 A IS 5809A IS 5809 A IS5809 A IS 5809A
Authority
IS
Iceland
Prior art keywords
acat
treatment
mmp inhibitors
concomitant administration
fat degeneration
Prior art date
Application number
IS5809A
Other languages
Icelandic (is)
Inventor
Michael Andrew Bocan Thomas
Original Assignee
Warner-Lambert Company, , Delaware Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company, , Delaware Corporation filed Critical Warner-Lambert Company, , Delaware Corporation
Publication of IS5809A publication Critical patent/IS5809A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
IS5809A 1998-07-21 2001-01-12 Concomitant administration of ACAT and MMP inhibitors for the treatment of fat degeneration IS5809A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
IS5809A true IS5809A (en) 2001-01-12

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5809A IS5809A (en) 1998-07-21 2001-01-12 Concomitant administration of ACAT and MMP inhibitors for the treatment of fat degeneration

Country Status (25)

Country Link
EP (1) EP1098662A2 (en)
JP (1) JP2002521328A (en)
KR (1) KR20010083134A (en)
CN (1) CN1310629A (en)
AP (1) AP2001002035A0 (en)
AU (1) AU4701799A (en)
BG (1) BG105162A (en)
BR (1) BR9912296A (en)
CA (1) CA2335062A1 (en)
CZ (1) CZ2001126A3 (en)
EA (1) EA200100153A1 (en)
EE (1) EE200100046A (en)
HR (1) HRP20010055A2 (en)
HU (1) HUP0102880A3 (en)
ID (1) ID30030A (en)
IL (1) IL140982A0 (en)
IS (1) IS5809A (en)
NO (1) NO20010291L (en)
OA (1) OA11584A (en)
PL (1) PL346011A1 (en)
SK (1) SK502001A3 (en)
TR (1) TR200100205T2 (en)
WO (1) WO2000004892A2 (en)
YU (1) YU3501A (en)
ZA (1) ZA200100294B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414848A (en) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Prevention of plaque rupture by ACAT inhibitors
DOP2000000107A (en) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc COMPOUNDS, COMPOSITIONS AND METHODS TO STIMULATE THE GROWTH AND LENGTH OF NEURONS
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
HUP0301728A3 (en) * 2000-09-01 2004-05-28 Sankyo Co Hmg-coa reductase inhibiting pharmaceutical compositions and their use
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
BR0308908A (en) * 2002-04-03 2005-01-04 Topotarget Uk Ltd Compound, composition, use of a compound, and methods for inhibiting hdac in a cell for the treatment of an hdac-mediated condition, a proliferative condition, cancer, and psoriasis
AU2003267991B2 (en) * 2002-07-11 2009-10-08 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (en) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 Use of group of carbamyl phenylsulfonyl compounds
EP3244883A1 (en) * 2015-01-15 2017-11-22 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (en) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 The effective extract component of river hazel and its application in prevention and treatment atherosclerosis
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CA2221729A1 (en) * 1995-08-04 1997-02-20 Warner-Lambert Company Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
ATE207891T1 (en) * 1996-05-17 2001-11-15 Warner Lambert Co BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS
KR20000068414A (en) * 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Matrix Metalloproteinase Inhibitors and their Therapeutic Uses

Also Published As

Publication number Publication date
CZ2001126A3 (en) 2002-01-16
HRP20010055A2 (en) 2002-04-30
ID30030A (en) 2001-11-01
OA11584A (en) 2004-07-20
CA2335062A1 (en) 2000-02-03
HUP0102880A2 (en) 2002-06-29
IL140982A0 (en) 2002-02-10
JP2002521328A (en) 2002-07-16
WO2000004892A2 (en) 2000-02-03
WO2000004892A3 (en) 2000-05-18
ZA200100294B (en) 2002-01-10
AU4701799A (en) 2000-02-14
NO20010291D0 (en) 2001-01-18
BR9912296A (en) 2001-04-17
HUP0102880A3 (en) 2002-11-28
NO20010291L (en) 2001-01-18
CN1310629A (en) 2001-08-29
EE200100046A (en) 2002-06-17
EP1098662A2 (en) 2001-05-16
EA200100153A1 (en) 2001-08-27
YU3501A (en) 2005-06-10
AP2001002035A0 (en) 2001-03-31
TR200100205T2 (en) 2001-05-21
PL346011A1 (en) 2002-01-14
KR20010083134A (en) 2001-08-31
SK502001A3 (en) 2002-06-04
BG105162A (en) 2001-12-29

Similar Documents

Publication Publication Date Title
NO20004098L (en) Methods and preparations for the treatment of macrophage-mediated disorders
IS5405A (en) Prostaglandin agonists and their use in the treatment of bone disorders
IS2457B (en) Compositions of drugs (e.g. chlorpromazine and pentamidine) for the treatment of neoplastic disorders
IS6560A (en) Pharmaceutical composition for the treatment of acute, persistent pain and / or nervous system pain and migraine
IS5500A (en) Medicinal preparations for the stimulation and treatment of gastrointestinal disorders and related diseases
NO994613D0 (en) Procedures and preparations for the treatment of sleep apnea
IS5898A (en) 5HT1 receptor agonists and metoclopramide for the treatment of migraine
DK0927555T3 (en) Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia
NO994778D0 (en) Methods and compositions for the treatment of intestinal inflammation
NO990296D0 (en) The HPPD gene and inhibitors
EP1087770A4 (en) INHIBITORS OF PRENYL PROTEIN TRANSFERASE
NO20011964L (en) Well treatment fluids and methods for using them
NO983576D0 (en) Well treatment fluids and methods
NO20031152D0 (en) Fertilization prevention method and method of administration for the same
NO993868D0 (en) 3-piperidyl-4-oxoquinazoline derivatives and medical preparations containing them
IS5233A (en) Diagnosis of reward deficiency syndrome and its preparations
IS5220A (en) Cyclo-oxygenase-2 selective carprofen for the treatment of pain and inflammation in dogs
NO20002181D0 (en) Sterilization wrap, its use and method of sterilization
DK1041985T3 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for the treatment of prophylactic disorders
DK1017388T3 (en) Pharmaceuticals containing ibuprofen and domperidone for the treatment of migraine
NO20010464L (en) Methods and Preparations for the Treatment of Gastroesophageal Reflux Syndrome
NO20012738D0 (en) Therapeutic products and their use
NO20010291D0 (en) Co-administration of ACAT and MMP inhibitors for the treatment of atherosclerotic wounds
IS6707A (en) Preparation for the prevention and treatment of cancer
NO20013816L (en) Benzamide derivatives and drugs containing them